InvestorsHub Logo
Followers 466
Posts 26938
Boards Moderated 2
Alias Born 09/11/2006

Re: None

Wednesday, 04/10/2013 9:15:39 PM

Wednesday, April 10, 2013 9:15:39 PM

Post# of 1397
4:01PM MEI Pharma's mitochondrial inhibitor drug candidate ME-344 delays tumor growth in recurrent ovarian cancer model (MEIP) 8.23 +0.18 : Co announced the presentation of new data showing the ability of its mitochondrial inhibitor drug candidate, ME-344, to decrease tumor burden and delay recurrence in a pre-clinical in vivo model of recurrent epithelial ovarian cancer, the most lethal of all gynecologic malignancies. Data from an ongoing Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is expected in June 2013.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MEIP News